Designing dual-target bioPROTACs and dissecting how tumours escape targeted degradation. Built a tumour-specific, DNA-encoded bioPROTAC co-degrading ERα and PI3K p85α that acts synergistically with tamoxifen in resistant breast cancer cells (CI < 0.4), and engineered a KRAS-targeting degrader on a TRIM21–RBCC scaffold — then traced a hypervariable-region mutation driving degradation escape, using 200-ns all-atom molecular dynamics of the farnesylated, membrane-embedded protein alongside cross-validated proteomic and ubiquitomic profiling.

Reproduced the CLAIRE de novo binder-design pipeline (Rosetta motif matching, ProteinMPNN, AlphaFold2 self-consistency) end-to-end for three small-molecule targets, building the compute environment from scratch and fixing a latent defect in the original codebase. Also extracted the computational recipe of Guo et al. (Science, 2025) from the primary literature and built a three-layer framework to test whether it generalises to KRAS.

Characterised the PGAM5–OGT interaction and its role in protein stability and tumour invasion; contributed to an NSFC project on P311 regulation of Periostin translation in pancreatic cancer metastasis (Grant 32000543); and built SARS-CoV-2 replicon deletion and mutation models, identifying nsp13-C16446T as an enhancer of the nsp12 interaction.